SureTrader Nadex Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: MyDogBuster, Dip66, simon wagstaff, $Pistol Pete$
Search This Board: 
Last Post: 2/27/2017 4:29:28 PM - Followers: 545 - Board type: Free - Posts Today: 0


MultiCell Technologies, Inc. (MCET)

U.S. Reporting: SEC Filer 

Office: (401) 762-0045  |  Email: [email protected]  |  Web:

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)




MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS)
to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment
of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.



MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc.
68 Cumberland Street, Suite 301

Woonsocket, RI 02895

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Statement of Ownership (sc 13g) 02/14/2017 06:14:05 AM
MCET News: Termination of Registration of a Class of Security Under Section 12(g) (15-12g) 01/13/2017 06:03:38 AM
MCET News: Current Report Filing (8-k) 09/26/2016 04:12:21 PM
#42600  Sticky Note $MCET OXIS INTERNATIONAL INC - FORM S-1/A - $Pistol Pete$ 02/06/17 02:46:13 PM
#42588  Sticky Note Cellular Immunotherapy for Multiple Myeloma Advancing Rapidly TPX 02/06/17 10:41:58 AM
#42758   Close .0001 Good job Barb and Gerald way Dip66 02/27/17 04:29:28 PM
#42757   No bid on the way? How is La Dip66 02/27/17 02:04:12 PM
#42756   MultiCell IR: Barbara Corbett: 941-637-9883 Dip66 02/27/17 09:01:46 AM
#42755   Nah.... there have been a few zero Shut up 02/24/17 11:31:35 AM
#42754   0 volume. Officially out of business? Dip66 02/24/17 10:16:49 AM
#42753   MultiCell Immunotherapeutics, Inc.: OXS-4235 for Multiple Myeloma and TPX 02/23/17 07:35:43 PM
#42752   OXS-2175 / MultiCell Technologies, Inc. TPX 02/23/17 07:31:40 PM
#42750   $MCET 3 Months Chart $Pistol Pete$ 02/22/17 06:28:03 PM
#42749   2017 looking like a complete waste for MCET. Dip66 02/22/17 09:35:45 AM
#42748   miRNA Modulators of Transcription Factor Targets: Potential Treatments TPX 02/22/17 07:05:16 AM
#42747   Seems more than a little murky to me. simon wagstaff 02/21/17 11:17:44 PM
#42746   OXS-4235 / MultiCell Technologies, Inc. TPX 02/21/17 06:48:50 PM
#42745   Under the terms of the agreement, MCIT will TPX 02/21/17 06:45:59 PM
#42744   That was BCLBCL I think, who is loaded simon wagstaff 02/21/17 06:11:47 PM
#42743   TPX how about that Jan PR? pfff. Dip66 02/21/17 01:21:42 PM
#42742   It actually has less to do with MCET simon wagstaff 02/21/17 11:06:49 AM
#42741   MultiCell IR: Barbara Corbett: 941-637-9883 Dip66 02/21/17 09:50:55 AM
#42740   That is HUGE for MCET! TPX 02/21/17 08:50:34 AM
#42739   Global Antibodies Market surpass US$ 341 Bn in TPX 02/17/17 01:11:52 PM
#42738   Pinning a bull’s-eye on cancer cells TPX 02/17/17 01:09:12 PM
#42737   Global Antibody Drug Conjugates Market By Drug (ADCETRIS, TPX 02/17/17 01:06:08 PM
#42736   Antibody-Drug Conjugates: Catalysts for Chemistry TPX 02/17/17 01:04:18 PM
#42735   Keeping Pace With the Immunotherapy Revolution TPX 02/17/17 12:55:53 PM
#42734   MultiCell IR: Barbara Corbett: 941-637-9883 Dip66 02/17/17 11:10:26 AM
#42733   Global Cancer Immunotherapies Market to 2022: Market is TPX 02/16/17 01:49:10 PM
#42732   LMOA!!! Pretty scary.... Shut up 02/16/17 01:35:44 PM
#42731   Somebody slacking today, only 25 post so far. simon wagstaff 02/16/17 12:27:44 PM
#42730   New process creates armies of T cells to TPX 02/16/17 12:00:29 PM
#42729   Combination of drugs may help cure brain cancer TPX 02/16/17 11:55:49 AM
#42728   0 volume officially out of business? Dip66 02/16/17 10:09:38 AM
#42727   MultiCell IR: Barbara Corbett: 941-637-9883 Dip66 02/16/17 09:47:28 AM
#42726   $MCET Trader's Cheat Sheet $Pistol Pete$ 02/15/17 07:13:57 PM
#42725   He's posted on over 20 different boards today. simon wagstaff 02/15/17 12:31:53 PM
#42724   Xenogenics is done, I guess you missed that. simon wagstaff 02/15/17 12:29:30 PM
#42723   TPX Don't you think MultiCell should fix their website Dip66 02/15/17 11:59:52 AM
#42722   What is the logic behind all this pumping? Shut up 02/15/17 11:34:45 AM
#42721   Lol! Really? simon wagstaff 02/15/17 09:46:46 AM
#42720   Hit to 4s coming soon! TPX 02/15/17 09:36:11 AM
#42719   3s are super thin!!! Glad I've loaded up BCLBCL 02/15/17 09:33:39 AM
#42718   Faris at MCET maybe 10 years ago. MCET simon wagstaff 02/14/17 02:20:15 PM
#42717   Ronald Faris, PhD, is the Director of Cell TPX 02/14/17 12:19:17 PM
#42716   Exactly!!!! Thanks Simon!!! Shut up 02/14/17 10:17:02 AM
#42715   There is nothing left to lie about that simon wagstaff 02/14/17 09:51:02 AM
#42714   What happened to the good ol' days when Dip66 02/14/17 09:41:32 AM
#42713   Lol! poor shareholders. meaningless, not even from simon wagstaff 02/14/17 08:41:32 AM
#42712   This stock is alive & well! Expecting major BCLBCL 02/14/17 07:39:06 AM
#42711   Yes it means that there are 5 billion presidentsclub 02/14/17 07:35:40 AM
#42710   Interesting! Filing is out there! TPX 02/14/17 06:41:49 AM
#42709   SC 13G filing out! TPX 02/14/17 06:32:20 AM